Healthcare

MicroPort Scientific makes medical devices for cardiovascular care, orthopedics, rhythm management, neurovascular treatment, and robotics. Revenue has grown and costs have improved, making the company notable as a medical device recovery case with multiple growth platforms.

MBX Biosciences is building long-acting peptide treatments for rare endocrine disorders, with market interest rising alongside pipeline progress. Its low-debt balance sheet and focused clinical strategy make execution on upcoming milestones especially important to watch.

Legend Biotech has evolved beyond a lab-stage biotech into a commercial cell-therapy company with revenue above $1 billion, powered by CARVYKTI. The key question is no longer demand, but how efficiently that growth can turn into lasting profits.

iRhythm builds wearable cardiac monitoring services around its Zio platform, a focused niche with durable healthcare demand. Strong revenue growth, improving cash flow, and narrowing losses make the company notable, even as the next phase depends on margin execution.

Disc Medicine is building a focused rare-blood-disorder pipeline around iron and heme biology. Its appeal lies in specialized science, multiple clinical catalysts, and low debt, while the long-term outcome depends on turning research progress into approved therapies.

Immunome is building a focused oncology pipeline around targeted antibodies and ADCs, supported by a low-debt balance sheet and added platform depth from Morphimmune. Its appeal rests on whether upcoming clinical progress can validate a rapidly expanding cancer franchise.

IDEAYA Biosciences is building targeted cancer drugs around genetic weaknesses in tumors, with a focused precision oncology pipeline, strong recent growth signals, and very low debt. The big question is whether clinical progress can turn scientific promise into lasting economics.